Analysts Set DaVita Inc. (NYSE:DVA) Target Price at $157.00

Shares of DaVita Inc. (NYSE:DVA) have received a consensus rating of “Hold” from the five brokerages that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $157.00.

A number of analysts have recently weighed in on DVA shares. UBS Group boosted their target price on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Bank of America boosted their target price on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a report on Wednesday, August 7th. TD Cowen boosted their target price on shares of DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. StockNews.com downgraded shares of DaVita from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 8th. Finally, Truist Financial upped their price target on shares of DaVita from $150.00 to $165.00 and gave the company a “hold” rating in a report on Tuesday, August 20th.

Insider Activity at DaVita

In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total value of $1,148,771.97. Following the transaction, the insider now directly owns 83,011 shares in the company, valued at approximately $12,137,038.31. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total value of $1,148,771.97. Following the transaction, the insider now directly owns 83,011 shares in the company, valued at approximately $12,137,038.31. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Michael David Staffieri sold 9,539 shares of the company’s stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $150.03, for a total transaction of $1,431,136.17. Following the completion of the transaction, the chief operating officer now owns 241,945 shares in the company, valued at $36,299,008.35. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 173,482 shares of company stock worth $27,387,069. Insiders own 2.00% of the company’s stock.

Institutional Investors Weigh In On DaVita

Several hedge funds have recently modified their holdings of DVA. International Assets Investment Management LLC purchased a new stake in shares of DaVita in the 4th quarter worth approximately $1,097,000. Principal Securities Inc. purchased a new stake in shares of DaVita in the 4th quarter worth approximately $37,000. Envestnet Portfolio Solutions Inc. lifted its position in shares of DaVita by 2.6% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 29,566 shares of the company’s stock worth $3,097,000 after purchasing an additional 740 shares during the period. Meridian Wealth Management LLC lifted its position in shares of DaVita by 2.9% in the 4th quarter. Meridian Wealth Management LLC now owns 5,921 shares of the company’s stock worth $620,000 after purchasing an additional 166 shares during the period. Finally, Kentucky Retirement Systems Insurance Trust Fund purchased a new stake in shares of DaVita in the 4th quarter worth approximately $201,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Stock Down 0.6 %

Shares of DVA stock opened at $163.16 on Thursday. The company has a market capitalization of $14.31 billion, a price-to-earnings ratio of 18.54, a PEG ratio of 0.95 and a beta of 0.87. DaVita has a one year low of $71.51 and a one year high of $166.04. The company’s fifty day moving average price is $146.25 and its 200-day moving average price is $140.54. The company has a debt-to-equity ratio of 9.94, a current ratio of 1.16 and a quick ratio of 1.12.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.47 by $0.12. The company had revenue of $3.19 billion for the quarter, compared to the consensus estimate of $3.15 billion. DaVita had a net margin of 6.86% and a return on equity of 77.00%. DaVita’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.08 EPS. Sell-side analysts expect that DaVita will post 9.99 EPS for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.